Roche details Tamiflu production capacity

Share this article:
Roche said its current production network was on track to produce 300 million treatments of Tamiflu annually by 2007 and negotiations with third parties to produce the drug have begun.
Roche said in a statement today that it had received more than 150 requests from third parties to produce Tamiflu and it was in early talks with eight companies, amongst them large generic manufacturers, pharmaceutical firms and governments.
"Patients' needs in case of a pandemic remain our top priority. William Burns, CEO of Roche's pharma division, said in a statement. "We have continually increased our production capacities and are now putting in place the means to increase production of Tamiflu to 300 million treatments as of 2007. In addition, we have entered into discussions with a number of interested parties to expand world wide supply, so governments can be as prepared as possible for when the influenza pandemic happens."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...